GPCR Structure Therapeutics Inc. American
Company Analysis
Latest News
🔴 Structure Therapeutics falls 4.2% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Structure Therapeutics falls 4.4% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Structure Therapeutics is trading 4.3% up in pre-market as biotech stocks rally broadly
Structure Therapeutics is trading 4.3% up at $56.47 after biotechnology stocks rallied broadly in pre-market trading. - The latest official update was August...
🔴 Structure Therapeutics is trading 5% down in after-hours trading with no clear catalyst identified
Structure Therapeutics is trading 4.94% down now at $52.00 after closing at $54.70 on August 13, 2026, with no clear company-specific catalyst identified. -...
🔴 Structure Therapeutics is trading 7.92% down in after-hours trading
Structure Therapeutics is trading 7.92% down in after-hours trading at $48.00, with no reliable company-specific announcement or late-breaking event identified...
🟢 Structure Therapeutics is trading 5% up in pre-market after Phase 3 ACCOMPLISH dosing
Structure Therapeutics is trading at $55.72, +4.86%, after announcing Phase 3 ACCOMPLISH dosing for aleniglipron in obesity trials. - Up to 4,700 patients are...
Structure Therapeutics initiates Phase 3 obesity trials and reports $1.3B cash in second quarter 2026
Structure Therapeutics reported a net loss of $106.2 million for the second quarter 2026, driven by a substantial increase in research and development...
🟢 Structure Therapeutics rises 4.0% — Biotech Sector Rallies on Argenx-Forte M&A Deal
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is trading higher, with the XBI ETF...
🟢 Structure Therapeutics is trading 4.1% up today as biotech sector rallies
Structure Therapeutics is trading 4.1% up at $50.32 as biotech shares continue to rally amid a broader risk-on environment. • The sector backdrop remains...
Structure Therapeutics Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
For the second quarter of 2026, analysts expect Structure Therapeutics to report a net loss of $0.39 per share on zero revenue, while the current stock price...
🔴 Structure Therapeutics is trading 4.3% down today in a consolidation move following a sharp biotech-led rebound
Structure Therapeutics is trading at $47.14 (down 4.3%) in a consolidation move following a sharp two-day biotech-led rally. • The stock previously climbed to...
🟢 Structure Therapeutics is trading 4.1% up today amid a broader biotech and market rally
Structure Therapeutics is trading 4.1% higher at $51.50 in pre-market, continuing a strong rebound driven by a broader biotech rally and improving risk...
🟢 Structure Therapeutics is trading 4.4% up today amid a broader biotech and market rally
Structure Therapeutics is trading 4.4% up at $49.45 as part of a broader risk-on move across the biotech sector and major U.S. indices. • The stock is...
🟢 Structure Therapeutics is trading 5.5% up today amid broader market strength and no company-specific news
Structure Therapeutics is trading at $49.94 (+5.47%) in pre-market as the stock gains alongside a broader market rally despite no clear company-specific...
🔴 Structure Therapeutics is trading 4.5% down today amid broader sector consolidation and risk-off pressure
Structure Therapeutics is trading at $46.51 (-4.48%) in pre-market amid broader sector consolidation and risk-off pressure, as no clear company-specific...
🟢 Structure Therapeutics rises 4.4% — Biotech Sector Rallies on Blockbuster M&A Deal and Positive Trial Data
With Biotech (XBI) up 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🟢 Structure Therapeutics is trading 4.1% up today on strong Phase 2b data for oral GLP-1 candidate
Structure Therapeutics is trading 4.1% up now at $48.91 as investors continue to react to strong Phase 2b data for its oral GLP-1 obesity candidate,...
🟢 Structure Therapeutics is trading 4.2% up today on continued momentum from positive GLP-1 trial data
Structure Therapeutics is trading 4.2% up at $48.97 in pre-market action, resuming its upward trend following a brief pullback on July 20. • The stock's...
🔴 Structure Therapeutics is trading 4.2% down today on profit-taking after recent GLP-1 rally
Structure Therapeutics is trading at $46.45, down 4.2% today, as the stock undergoes profit-taking following a sharp multi-day rally driven by positive...
🟢 Structure Therapeutics Soars 4.6% on Positive GLP-1 Phase 2b Data and Strong Institutional Interest Amid Biotech Weakness
Structure Therapeutics is trading at $48.14 (+4.58%) today, driven by recent positive Phase 2b trial results for its oral GLP-1 obesity drug aleniglipron,...